GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (XTAE:ENLV) » Definitions » 3-Year Revenue Growth Rate

Enlivex Therapeutics (XTAE:ENLV) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Enlivex Therapeutics 3-Year Revenue Growth Rate?

Enlivex Therapeutics's Revenue per Share for the three months ended in Sep. 2024 was ₪0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of Enlivex Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Enlivex Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enlivex Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's 3-Year Revenue Growth Rate falls into.



Enlivex Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Enlivex Therapeutics  (XTAE:ENLV) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Enlivex Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Ness Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics Headlines

From GuruFocus